The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

There are currently no approved treatments in Canada that can slow the progression of Alzheimer's, only drugs to quiet ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Neurons that die early in Alzheimer’s help drive brain waste removal. Treating this process sooner could change outcomes.

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

The annual review of clinical trials for Alzheimer’s highlights a growing number of active trials and drugs that could help ...

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...